AnaptysBio, Inc. ANAB Proceeds From Sale And Maturity Of Available For Sale Securities
Proceeds From Sale And Maturity Of Available For Sale Securities at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about AnaptysBio, Inc.'s proceeds from sale and maturity of available for sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AnaptysBio, Inc.'s proceeds from sale and maturity of available for sale securities?
- AnaptysBio, Inc. (ANAB) reported proceeds from sale and maturity of available for sale securities of $35M in Q1 2026.
- How has AnaptysBio, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?
- AnaptysBio, Inc.'s proceeds from sale and maturity of available for sale securities decreased by 74.5% year-over-year, from $137.43M to $35M.
- What is the long-term trend for AnaptysBio, Inc.'s proceeds from sale and maturity of available for sale securities?
- Over 4 years (2021 to 2025), AnaptysBio, Inc.'s proceeds from sale and maturity of available for sale securities has grown at a 27.9% compound annual growth rate (CAGR), from $158.85M to $424.53M.